Hypersensitivity - Pipeline Review, H1 2016

  • ID: 3714962
  • Report
  • 41 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • MORE
Hypersensitivity - Pipeline Review, H1 2016

Summary

‘Hypersensitivity - Pipeline Review, H1 2016’, provides an overview of the Hypersensitivity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypersensitivity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersensitivity and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypersensitivity
- The report reviews pipeline therapeutics for Hypersensitivity by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hypersensitivity therapeutics and enlists all their major and minor projects
- The report assesses Hypersensitivity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypersensitivity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hypersensitivity
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypersensitivity pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hypersensitivity Overview

Therapeutics Development

Pipeline Products for Hypersensitivity - Overview

Pipeline Products for Hypersensitivity - Comparative Analysis

Hypersensitivity - Therapeutics under Development by Companies

Hypersensitivity - Therapeutics under Investigation by Universities/Institutes

Hypersensitivity - Pipeline Products Glance

Early Stage Products

Hypersensitivity - Products under Development by Companies

Hypersensitivity - Products under Investigation by Universities/Institutes

Hypersensitivity - Companies Involved in Therapeutics Development

Anacor Pharmaceuticals, Inc.

Eisai Co., Ltd.

Ensemble Therapeutics Corporation

F. Hoffmann-La Roche Ltd.

JW Pharmaceutical Corporation

Thesan Pharmaceuticals, Inc.

Hypersensitivity - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AN-3485 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ARN-077 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BD-750 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CWF-0808 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

E-34935 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

E-35018 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit CCL20 for Arthritis and Contact Hypersensitivity - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OA-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Peptide to Inhibit Calcineurin for Rheumatoid Arthritis and Hypersensitivity - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein to Activate Gal-1 for Immunology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

RN-486 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Hypersensitivity - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hypersensitivity, H1 2016

Number of Products under Development for Hypersensitivity - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Hypersensitivity - Pipeline by Anacor Pharmaceuticals, Inc., H1 2016

Hypersensitivity - Pipeline by Eisai Co., Ltd., H1 2016

Hypersensitivity - Pipeline by Ensemble Therapeutics Corporation, H1 2016

Hypersensitivity - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Hypersensitivity - Pipeline by JW Pharmaceutical Corporation, H1 2016

Hypersensitivity - Pipeline by Thesan Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Hypersensitivity - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Hypersensitivity - Comparative Analysis, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Anacor Pharmaceuticals, Inc.
Eisai Co., Ltd.
Ensemble Therapeutics Corporation
F. Hoffmann-La Roche Ltd.
JW Pharmaceutical Corporation
Thesan Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll